Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123224) titled 'Real-World Study of Polatuzumab Vedotin-Containing Regimens in Previously Untreated Diffuse Large B-Cell Lymphoma and the Expression and Clinical Significance of 5-hmC: A Retrospective Case Series' on April 23.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
Condition:
Diffuse large B cell lymphoma
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-17
Target Sample Size: Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who received first-line treatment with vilpotuzumab:55;
Countries...